<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> is a major public health problem leading to high rates of <z:hpo ids='HP_0011420'>death</z:hpo> and disability in adults </plain></SENT>
<SENT sid="1" pm="."><plain>Excessive stimulation of <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> receptors (NMDARs) and the resulting neuronal nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (nNOS) activation are crucial for neuronal injury after <z:hpo ids='HP_0001297'>stroke</z:hpo> insult </plain></SENT>
<SENT sid="2" pm="."><plain>However, directly inhibiting NMDARs or nNOS can cause severe side effects because they have key physiological functions in the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Here we show that <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> induces the interaction of nNOS with postsynaptic density protein-95 (PSD-95) </plain></SENT>
<SENT sid="4" pm="."><plain>Disrupting nNOS-PSD-95 interaction via overexpressing the <z:chebi fb="0" ids="33712">N-terminal amino acid residues</z:chebi> 1-133 of nNOS (nNOS-N(1-133)) prevented <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi>-induced excitotoxicity and cerebral ischemic damage </plain></SENT>
<SENT sid="5" pm="."><plain>Given the mechanism of nNOS-PSD-95 interaction, we developed a series of compounds and discovered a small-molecular inhibitor of the nNOS-PSD-95 interaction, ZL006 </plain></SENT>
<SENT sid="6" pm="."><plain>This drug blocked the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced nNOS-PSD-95 association selectively, had potent neuroprotective activity in vitro and ameliorated focal cerebral ischemic damage in mice and rats subjected to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) and reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, it readily crossed the blood-brain barrier, did not inhibit NMDAR function, catalytic activity of nNOS or spatial memory, and had no effect on <z:hpo ids='HP_0000718'>aggressive behaviors</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, this new drug may serve as a treatment for <z:hpo ids='HP_0001297'>stroke</z:hpo>, perhaps without major side effects </plain></SENT>
</text></document>